Anhui Huaan Health Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 15th Meeting of the 5th Board of Directors
The company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false representations, misleading statements, or material omissions.
I. Convening of the Board Meeting
The 15th meeting of the 5th Board of Directors of Anhui Huaan Health Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was convened. Notice was sent by written means and email on August 5, 2026. The meeting was held on August 10, 2026, in Meeting Room 1501, Building A1, Company Headquarters, through a combination of on-site and remote communication. Nine directors were eligible to attend, and all nine attended. Directors Lu Xu, Yin Jun, Liu Liang, Cheng Mou, and Li Chuanrun attended via remote communication. The meeting was convened and presided over by Mr. He Jiale, Chairman of the Company. Senior management personnel of the Company attended the meeting. The convening and holding of this meeting comply with relevant laws, regulations, and the Articles of Association, and the resolutions made are legal and valid.
II. Deliberation of the Board Meeting
The following proposals were deliberated and approved at this meeting:
- Proposal on the Company's Compliance with Conditions for Targeted Issuance of A-shares
In accordance with the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Administrative Measures for the Registration of Securities Issuances by Listed Companies," and other relevant laws, regulations, and normative documents, and based on the Company's actual situation, a thorough self-inspection and verification were conducted against the requirements for targeted issuance of A-shares by GEM-listed companies. It is determined that the Company meets all the provisions and requirements for the targeted issuance of A-shares and possesses the qualifications and conditions for such issuance.
Voting Results: 9 votes in favor, 0 abstentions, 0 votes against, 0 abstentions.
This proposal has been deliberated and approved by the Company's Board Audit Committee, Strategy Committee, and Independent Directors' Special Committee.
This proposal still needs to be submitted to the First Extraordinary General Meeting of Shareholders in 2026 for consideration.
- Deliberation and Approval of the "Proposal on the Company's Plan for Targeted Issuance of A-shares in 2026"
To meet the Company's business development needs, the Company plans to conduct a targeted issuance of A-shares (hereinafter referred to as the "Current Issuance"). The Company's plan for the targeted issuance of A-shares in 2026 is as follows:
2.01 Type and Par Value of Shares to be Issued
The shares to be issued in this targeted offering will be domestic RMB ordinary shares (A-shares) listed in China, with a par value of RMB 1.00 per share.
2.02 Issuance Method and Timing
The Current Issuance will be conducted entirely through a targeted issuance method. After the Shenzhen Stock Exchange (hereinafter referred to as the "SZSE") review and the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") approval for registration, the Company will issue the shares opportunistically within the validity period. If there are new provisions in national laws or regulations, the Company will adjust accordingly.
2.03 Issuance Targets and Subscription Method
The number of issuance targets for this targeted issuance shall not exceed 35 (inclusive). The targets must be qualified investors as stipulated by the CSRC, including fund management companies, securities companies, insurance institutional investors, trust companies, financial companies, qualified foreign institutional investors, and other legal persons, natural persons, or other qualified investors. If a fund management company, securities company, or qualified foreign institutional investor subscribes with more than two products they manage, it will be considered as one issuance target. If a trust company is an issuance target, it can only subscribe with its own funds.